Morgan Stanley has named several buy-rated global stocks it expects to beat the market.
"We expect Ozempic to drive a further upgrade to guidance before the 2Q results," the analysts wrote — the company reports on Aug. 10.
Other drugmakers the bank is positive on are Grifols , where the bank expects a "solid performance," and Indivior , which is set for a "strong quarter," Morgan Stanley said.
French materials manufacturer Saint-Gobain is also a Morgan Stanley pick, with the bank saying that consensus has not yet priced in its management's optimism on margins discussed at its annual general meeting last month.
"While another positive beat ratio looks likely for 2Q23, a slowdown in global and European economic momentum suggests that the magnitude of the said beat will be closer to normal levels," they added.
Persons:
Morgan Stanley, Giorgio Magagnotti
Organizations:
Novo Nordisk, Deutsche Telekom, . Energy
Locations:
Germany